Abstract:Abstract There is a critical need to understand and overcome resistance to targeted therapy in cancer. While FDA-approved BRAF and MEK inhibitors achieve clinical responses in the majority of metastatic melanoma patients with a BRAFV600 mutation, a significant proportion of patients have minimal responses, and virtually all patients develop acquired resistance in a short period of time. We and others have shown that increased oxidative phosphorylation (OxPhos), which is critically dependent on the transcriptional co-activator PGC1α, can mediate de novo resistance to MAPK pathway inhibitors in melanomas with BRAFV600 mutations. We have also demonstrated that elevated OxPhos (a) mediates de novo resistance to MEK inhibitors in melanoma cell lines without BRAFV600 mutations; (b) characterizes 30-50% of BRAFV600-mutant cell lines and patients with acquired resistance to BRAF +/- MEK inhibitors; and (c) predicts sensitivity to dual inhibition of mTORC1/2 in vitro and in vivo. Inhibition of mTORC1/2 downregulates both PGC1α and OxPhos through a novel mechanism involving the subcellular localization of the transcription factor MITF. To further exploit the therapeutic potential of targeting OxPhos, we have evaluated the molecular and anti-melanoma activities of a novel OxPhos inhibitor, IACS-10759, developed at M.D. Anderson Cancer Center. IACS-10759 potently inhibits the electron transport chain Complex I of mitochondrial OxPhos at low nanomolar concentrations. Additionally, this molecule has favorable safety and pharmacokinetic profile in animal models. Normal melanocytes, skin fibroblasts and most melanoma cell lines were not sensitive to micromolar doses of IACS-10759. However, a subset of de novo and acquired resistant melanomas with high OxPhos were sensitive to low nanomolar concentrations of IACS-10759 and underwent apoptotic cell death with treatment. An additional subset of melanomas were sensitive to the combination of IACS-10759 with MEK or BRAF inhibitors. Early functional studies revealed AMPK-activation associated effects as mediators of sensitivity, in addition to the inability of the cells to use alternate metabolic pathways for energy generation. Our findings demonstrate that a high OxPhos metabolic phenotype is associated with de novo and acquired resistance to MAPK pathway targeted therapies in melanoma, and support that targeting mTORC1/2 and the OxPhos complex 1 are promising strategies for counteracting this resistance. Citation Format: Vashisht Gopal Yennu-Nanda, Zeping Hu, Victoria M. Thiele, Tim Heffernan, Maria DiFrancesco, Joe Marszalek, Ralph Deberadinis, Michael A. Davies. Overcoming mitochondrial oxidative phosphorylation-mediated resistance to targeted therapies in melanoma. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr A52.

Overcoming Chemoresistance to B-Raf Inhibitor in Melanoma Via Targeted Inhibition of Phosphoenolpyruvate Carboxykinase1 Using 3-Mercaptopropionic Acid

Overcoming Chemoresistance to Vemurafenib in Melanoma Via Targeted Inhibition of PCK1 Using 3-Mercaptopropionic Acid

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

MOGAT3-Mediated DAG Accumulation Drives Acquired Resistance to Anti-BRAF/EGFR Therapy in BRAFV600E-Mutant Metastatic Colorectal Cancer.

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirin

CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway

Resistance Mechanism of the Oncogenic Β3‐αc Deletion Mutation in BRAF Kinase to Dabrafenib and Vemurafenib Revealed by Molecular Dynamics Simulations and Binding Free Energy Calculations

Targeted Therapy in Melanoma and Mechanisms of Resistance

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets

EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma

Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockade

Abstract A52: Overcoming Mitochondrial Oxidative Phosphorylation-Mediated Resistance to Targeted Therapies in Melanoma

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy

Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma